20 mins ago · China
Chinese drug iza-bren doubles lung cancer survival window in phase 3 trial
What's happening
SignalsMonitor is following this as a general story. South China Morning Post Asia is the outlet attached so far. The reports are tied to China. The first report grouped here was at 3 Nov 2026, 08:00 UTC. The headline in use is “Chinese drug iza-bren doubles lung cancer survival window in phase 3 trial”. This note is SignalsMonitor's own briefing, not the publisher's article.
What we know
An anticancer drug developed by Sichuan Biokin Pharmaceutical took centre stage in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress in Madrid last week. Researchers said the drug, iza-bren, showed a significant advantage over platinum-based chemotherapy in a phase 3 randomised, double-blind clinical trial conducted…
Story timeline
Reports grouped into this story, earliest first. Exact repeats from the same outlet are collapsed.
- First reported by South China Morning Post Asia
Chinese drug iza-bren doubles lung cancer survival window in phase 3 trial
Reported by 1 outlet
- South China Morning Post
- South China Morning PostChinese drug iza-bren doubles lung cancer survival window in phase 3 trial